Market Overview:
Q fever is a bacterial disease caused by the Coxiella burnetii bacterium. It usually manifests in flu-like symptoms and is fairly easy to treat. However, in a small percentage of patients, Q fever may present as a chronic disease. This chronic version of the disease can be much more dangerous, with potential implications for the patient’s cardiovascular system and the possible contraction of pneumonia, hepatitis, and encephalitis. The chronic version of Q fever is thus more feared and is the reason why considerable expenses have been made to counter the condition.
The global Q Fever Market is expected to exhibit a strong 7.83% CAGR over the forecast period from 2018 to 2023, according to the latest research report from Market Research Future (MRFR). The global Q fever market is thoroughly analyzed in the report in order to provide readers with a complete overview of the market’s major drivers and restraining factors, as well as the economic background of the market and the competitive landscape of the market. The global Q fever market is expected to reach a valuation of more than USD 6.2 million by 2023.
The effect of Q fever infection is mostly chronic however few cases may become acute. Some of the complications include encephalitis, hepatitis, splenomegaly, endocarditis and pneumonia. In acute q fever, hospitalization is highly likely.

Competitive Analysis:
• AtoxBio
• Yashica Pharmaceuticals
• Johnson & Johnson Services Inc
• Bayer AG
• Melinta Therapeutics Inc
• Sanofi SA
• Basilea Pharmaceutica Ltd
• Pfizer Inc
• Teva Pharmaceutical
• Merck KGaA

Segmentation:
• The global Q fever market is segmented on the basis of type, diagnosis, treatment, end use, and region.
• By type, the global Q fever market is segmented into acute and chronic. The chronic Q fever segment is the leading revenue generator and is likely to exhibit the higher CAGR over the forecast period.
• By diagnosis, the Q fever market is segmented into serology tests and others.
• By treatment, the global Q fever market is segmented into antibiotics and surgery. Surgery dominates the global Q fever market by treatment type, as it is a crucial accessory to treating chronic Q fever, where the damage may have spread to other organ systems in the body.
• By end use, the global Q fever market is segmented into patients, hospitals and clinics, and others. The patients segment held a dominant share of more than 72% in the global Q fever market in 2017.

Regional Analysis:
Asia Pacific, Americas (North America and South America), Europe are among the key regions covered in MRFR’s analysis. Asia Pacific is the largest market for q fever. In 2017, APAC accounted for 44.5% share of the global Q fever market in terms of revenue and is projected to capture 8.57% CAGR during the assessment period. High prevalence of bacterial infection, and high risk of epidemic developing countries in the region makes q fever a prudent disease in APAC. China and India have emerged as the two most significant markets for q fever in APAC. In addition, governments in these countries are increasing their focus on improving healthcare services as well as undertaking initiatives to spread awareness.
After Asia Pacific, the Q fever market is most attractive in Europe and North America. This is mainly due to factors such as high healthcare expenditure, high level of awareness and strong healthcare penetration. Prevalence of animal-transmitted diseases in these regions is moderate owing to existence of robust precautionary measures.